Registration of share capital increase in IDEX Biometrics (Tranche 1) 3 Jun 2023

Written by Customer Service on June 4, 2023. Posted in Public Companies.

Reference is made to the notice on 24 May 2023 regarding completion a private placement of 147.1 million shares at NOK 0.85 per share in IDEX Biometrics ASA. The placement was split in two tranches of 116.9 million shares and 30.2 million shares respectively. The capital increase of 116,897,492 Tranche 1 shares has been registered and the shares will be issued soonest. The company’s share capital is now NOK 192,880,861.80 divided into 1,285,872,412 shares, each with a nominal value of NOK 0.15. The issue of 30,161,332 Tranche 2 shares will be considered and resolved by an extraordinary general meeting of shareholders on 16 June 2023. For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: +47 918 00186 About IDEX BiometricsIDEX Biometrics (OSE: IDEX and Nasdaq: IDBA) is a leading...

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Written by Customer Service on June 4, 2023. Posted in Public Companies.

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in October 2023 Conference call and webcast today at 6:00 p.m. CT BRISBANE, Calif., June 04, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical Company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced new data from the registrational Phase 2 FIREFLY-1 trial evaluating the investigational agent tovorafenib (DAY101). These data were shared in an oral presentation today at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. In addition, the Company announced that it has initiated...

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

Written by Customer Service on June 4, 2023. Posted in Public Companies.

– Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment – – Trilaciclib Enhances Expression of Genes Associated with Memory T Cells – – Trilaciclib Increases Multiple Surrogate Immune Markers for Memory CD8+ T Cell Differentiation, Infiltration, and Function – RESEARCH TRIANGLE PARK, N.C., June 04, 2023 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from 24 patients enrolled in its Phase 2, single arm mechanism of action study of trilaciclib administered as a single agent to patients with early-stage triple-negative breast cancer (TNBC) prior to receiving trilaciclib and neoadjuvant therapy. These results highlight the potential for trilaciclib to enhance...

Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial

Written by Customer Service on June 3, 2023. Posted in Public Companies.

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical responses were reported in 8 out of 12 EVX-01 treated patients High-quality neoantigens, predicted by AI technology, were associated with longer progression-free survival Strong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients Higher EVX-01 dose induced a stronger immune response and was associated with improved clinical outcome COPENHAGEN, Denmark, June 03, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023...

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

Written by Customer Service on June 3, 2023. Posted in Public Companies.

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who represent 80% of the patient population, experienced substantial clinical benefit – – REFRaME-O1, the Phase 2/3 pivotal study of luvelta for patients with platinum-resistant ovarian cancer has been initiated and is open for enrollment – SOUTH SAN FRANCISCO, Calif., June 03, 2023 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that results from a Phase 1 dose-expansion study of luveltamab tazevibulin (luvelta), a novel...

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Written by Customer Service on June 3, 2023. Posted in Public Companies.

Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no progression in responding patients since the data snapshot presented in December 2022 Overall response rate (ORR) of 37.4%, with clinically meaningful activity across the range of anti-PD1 failed cutaneous melanoma settings enrolled, including in patients with moderate-high tumor burden and visceral disease RP2 demonstrated an acceptable benefit risk profile and meaningful antitumor activity in patients with uveal melanoma from the ongoing RP2 Phase 1 trial WOBURN, Mass., June 03, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed...

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

Written by Customer Service on June 3, 2023. Posted in Public Companies.

– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable 2nd-line GIST patients; data immature to estimate progression free survival (PFS) – Combination of bezuclastinib and sunitinib is well-tolerated and consistent with published sunitinib monotherapy safety profile – Cogent to host investor webcast Monday, June 5 at 8:00 a.m. ET WALTHAM, Mass. and BOULDER, Colo., June 03, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive lead-in data from its ongoing Phase 3 PEAK trial evaluating the selective KIT D816V inhibitor bezuclastinib in...

NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

Written by Customer Service on June 3, 2023. Posted in Public Companies.

– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p

BW Offshore: Short-term contract extension for Espoir Ivoirien

Written by Customer Service on June 3, 2023. Posted in Public Companies.

Short-term contract extension for Espoir Ivoirien BW Offshore has signed a short-term extension for the lease and operation of the FPSO Espoir Ivoirien in order to discuss a potential purchase of the FPSO by the client. The firm period has been extended until 9 June 2023. For further information, please contact:Ståle Andreassen, CFO, +47 91 71 86 55Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore:BW Offshore engineers innovative floating production solutions. The Company has a fleet of 8 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on...

Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan

Written by Customer Service on June 3, 2023. Posted in Public Companies.

Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohort AFM24 showed clinical activity in 7 out of 15 heavily pre-treated patients with tumor reductions, including 2 confirmed partial responses and 5 patients exhibiting stable disease In line with previous results, the majority of patients experienced only mild to moderate treatment-related adverse events, confirming a well-manageable safety profile in heavily pretreated patients, an important factor for combination regimens Based on the totality of data available to date, Affimed will focus clinical development of AFM24 on combination approaches, adding an EGFR mutant NSCLC cohort to the AFM24-102 study to evaluate therapeutic potential in combination with Roche’s PD-L1 checkpoint inhibitor atezolizumab Company...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice